Deleted Tweets From Scott Gottlieb, R-D.C.

RT @FDADeviceInfo: #MedicalDevice Safety Action Plan now available - our vision to protect patients and promote public health… https://t.co/SSGvtv5SlU

#FDA will be hosting a Patient-Focused Drug Development meeting July 9 to obtain patients’ perspectives on the impacts of chronic pain, views on treatment approaches and challenges or barriers to accessing treatments. More info on meeting coming soon: htt

Patient perspectives at 7/9 #PFDD meeting on chronic pain are critical as #FDA seeks to decrease opioid exposure while maintaining safe, effective, appropriate opioid prescribing for patients who need it, and fostering development of novel pain treatments

RT @US_FDA: Safety + Innovation: FDA’s Medical Device Safety Action Plan outlines measures to improve safety of medical devices… https://t.co/kbudDp6ygi

RT @benmoscovitch: Thread: New FDA plan outlines key steps the agency has taken, and plans to take, to improve #meddevice safety 1/ https:/… QT @US_FDA: Safety + Innovation: FDA’s Medical Device Safety Action Plan outlines measures to improve safety of medical devices… https://t.co/kbudDp6ygi)

My testimony today before House Appropriations Subcommittee re: #FDA’s FY19 budget request. We’re fortunate for bipartisan support received in recent years, reflecting shared obligation to agency’s vital role protecting & promoting public health https

#FDA’s FY19 budget request includes new resources to make significant investments and capitalize on remarkable opportunities we have to advance critical areas of science, domestic technology and public health https://t.co/WX96Wt3Nv7

#FDA’s sharp increase in disease-specific guidance documents once fully engaged and resourced would apply modern principles to make drug development more efficient by focusing on the most effective ways to prove safety and efficacy https://t.co/WX96Wt3Nv7

Investments in better regulatory tools, better management of our process and better science will help #FDA fulfill our critical consumer protection role and advance opportunities for Americans to improve their health https://t.co/WX96Wt3Nv7

RT @FDAMedia: Remarks from FDA Commissioner @SGottliebFDA on Fiscal Year 2019 budget request for FDA https://t.co/asiMrHJmvz

RT @califf001: Hooray for more frequent and disease specific guidance to keep the FDA and the R&D ecosystem at the top of its game. @DukeF… QT @SGottliebFDA: #FDA’s sharp increase in disease-specific guidance documents once fully engaged and resourced would apply modern pr… https://t.co/Otx33qNTeD)

RT @BioCentury: .@SGottliebFDA describes plans to use proposed funding boost to revamp drug reviews. FDA hopes to use the $ to writ… https://t.co/0KAgpy0QQW

RT @RAPSorg: .@US_FDA Plans to Ramp Up Disease-Focused Guidance, @SGottliebFDA Tells House Appropriations Subcommittee |… https://t.co/KVEzwf506X

RT @US_FDA: FDA’s Medical Device Safety Action Plan aims to ensure that new advances in technology that offer more capabilities… https://t.co/SvCaFiHctT

The new effort is one part of broader reforms aimed at bringing more consistency, collaboration, modern scientific tools across drug review; including development of a knowledge management system to allow our scientific precedents to be more easily access

#FDA is taking new steps to promote new drug innovation and make the development process more efficient, modern, and scientifically rigorous; among other steps, by developing many new disease focused guidance documents to outline updated approval standard

As part of a new initiative to promote drug innovation aimed at serious medical needs; #FDA is establishing new policy office as part of its new drug review program aimed at facilitating development of many more disease focused and cross cutting guidances

#FDA continues to issue new guidances related to the development path for complex drugs, which are sometimes harder for generics to copy. This latest FDA document address Quality Considerations for Metered Dose Inhaler and Dry Powder Inhaler Drug Products

RT @US_FDA: Pharmacists can be confident in the safety and effectiveness of generic medicines. For educational resources and mo… https://t.co/tmgcylNPOd

RT @dgingery: Even more Wednesday reading: #FDA Developing Database Of Medical Review Decisions, Gottlieb Tells Congress https://t.co/37v4ilxYga

RT @FDADeviceInfo: #MedicalDevice Safety Action Plan now available - our vision to protect patients and promote public health… https://t.co/SSGvtv5SlU

#FDA will be hosting a Patient-Focused Drug Development meeting July 9 to obtain patients’ perspectives on the impacts of chronic pain, views on treatment approaches and challenges or barriers to accessing treatments. More info on meeting coming soon: htt

Patient perspectives at 7/9 #PFDD meeting on chronic pain are critical as #FDA seeks to decrease opioid exposure while maintaining safe, effective, appropriate opioid prescribing for patients who need it, and fostering development of novel pain treatments

RT @US_FDA: Safety + Innovation: FDA’s Medical Device Safety Action Plan outlines measures to improve safety of medical devices… https://t.co/kbudDp6ygi

RT @benmoscovitch: Thread: New FDA plan outlines key steps the agency has taken, and plans to take, to improve #meddevice safety 1/ https:/… QT @US_FDA: Safety + Innovation: FDA’s Medical Device Safety Action Plan outlines measures to improve safety of medical devices… https://t.co/kbudDp6ygi)

My testimony today before House Appropriations Subcommittee re: #FDA’s FY19 budget request. We’re fortunate for bipartisan support received in recent years, reflecting shared obligation to agency’s vital role protecting & promoting public health https

#FDA’s FY19 budget request includes new resources to make significant investments and capitalize on remarkable opportunities we have to advance critical areas of science, domestic technology and public health https://t.co/WX96Wt3Nv7

#FDA’s sharp increase in disease-specific guidance documents once fully engaged and resourced would apply modern principles to make drug development more efficient by focusing on the most effective ways to prove safety and efficacy https://t.co/WX96Wt3Nv7

Investments in better regulatory tools, better management of our process and better science will help #FDA fulfill our critical consumer protection role and advance opportunities for Americans to improve their health https://t.co/WX96Wt3Nv7

RT @FDAMedia: Remarks from FDA Commissioner @SGottliebFDA on Fiscal Year 2019 budget request for FDA https://t.co/asiMrHJmvz

RT @califf001: Hooray for more frequent and disease specific guidance to keep the FDA and the R&D ecosystem at the top of its game. @DukeF… QT @SGottliebFDA: #FDA’s sharp increase in disease-specific guidance documents once fully engaged and resourced would apply modern pr… https://t.co/Otx33qNTeD)

RT @BioCentury: .@SGottliebFDA describes plans to use proposed funding boost to revamp drug reviews. FDA hopes to use the $ to writ… https://t.co/0KAgpy0QQW

RT @RAPSorg: .@US_FDA Plans to Ramp Up Disease-Focused Guidance, @SGottliebFDA Tells House Appropriations Subcommittee |… https://t.co/KVEzwf506X

RT @US_FDA: FDA’s Medical Device Safety Action Plan aims to ensure that new advances in technology that offer more capabilities… https://t.co/SvCaFiHctT

The new effort is one part of broader reforms aimed at bringing more consistency, collaboration, modern scientific tools across drug review; including development of a knowledge management system to allow our scientific precedents to be more easily access

#FDA is taking new steps to promote new drug innovation and make the development process more efficient, modern, and scientifically rigorous; among other steps, by developing many new disease focused guidance documents to outline updated approval standard

As part of a new initiative to promote drug innovation aimed at serious medical needs; #FDA is establishing new policy office as part of its new drug review program aimed at facilitating development of many more disease focused and cross cutting guidances

#FDA continues to issue new guidances related to the development path for complex drugs, which are sometimes harder for generics to copy. This latest FDA document address Quality Considerations for Metered Dose Inhaler and Dry Powder Inhaler Drug Products

RT @US_FDA: Pharmacists can be confident in the safety and effectiveness of generic medicines. For educational resources and mo… https://t.co/tmgcylNPOd

RT @dgingery: Even more Wednesday reading: #FDA Developing Database Of Medical Review Decisions, Gottlieb Tells Congress https://t.co/37v4ilxYga